¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2024 Á¦11ȸ ¾Æ»ê¾È°ú ½ÉÆ÷Áö¾ö-³ì³»Àå : 2024-02-04

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2024 Á¦11ȸ ¾Æ»ê¾È°ú ½ÉÆ÷Áö¾ö-³ì³»Àå : 2024-02-04
±³À°ÀÏÀÚ : 2024-02-04
±³À°Àå¼Ò : ¼­¿ï¾Æ»êº´¿ø µ¿°ü ´ë°­´ç

±³À°ÁÖÁ¦ : 2024 Á¦11ȸ ¾Æ»ê¾È°ú ½ÉÆ÷Áö¾ö-³ì³»Àå

ÁÖÃÖ±â°ü : ¼­¿ï¾Æ»êº´¿ø
´ã´çÀÚ : Á¤ÇýÀ±
¿¬¶ôó : 02-3010-3680  

À̸ÞÀÏ : hyeyun0527@amc.seoul.kr

±³À°Á¾·ù : ¾È°ú

Âü¼®¿¹»óÀÎ : 150¸í
Èñ¸ÁÆòÁ¡ : 5Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 50ºÐ

¼¼ºÎ¼ö°­·á : 80,000¿ø  

ºñ°í Àü¹®ÀÇ - »çÀü 60,000¿ø / ÇöÀå 80,000¿ø   Àü°øÀÇ - »çÀü 30,000¿ø / ÇöÀå 50,000¿ø


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 02¿ù 04ÀÏ µ¿°ü ´ë°­´ç 08:45~09:00 Event-based guidelines from recent landmark trials and studies ±è°íÀº(¿ï»êÀÇ´ë)

±³À°½Ã°£ 02¿ù 04ÀÏ µ¿°ü ´ë°­´ç 09:00~09:15 Emerging glaucoma medication ÀÌÅÂÀº(ÀüºÏÀÇ´ë)

±³À°½Ã°£ 02¿ù 04ÀÏ µ¿°ü ´ë°­´ç 09:15~09:30 MIGS - which device to choose for which patient ¹èÇü¿ø(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 02¿ù 04ÀÏ µ¿°ü ´ë°­´ç 09:30~09:45 Micropulse laser therapy vs slow coagulation CPC: which is better? ÃÖÀç¿Ï(¼¾Æ®·²¼­¿ï¾È°ú)

Åä·Ð 02¿ù 04ÀÏ µ¿°ü ´ë°­´ç 09:45~09:55 Discussion ()

±³À°½Ã°£ 02¿ù 04ÀÏ µ¿°ü ´ë°­´ç 09:55~10:10 Evolving concepts on aqueous outflow ÇÑÁ¾Ã¶(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 02¿ù 04ÀÏ µ¿°ü ´ë°­´ç 10:10~10:25 Disc hemorrhage: clinical significance in glaucoma ÀÌÀºÁö(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 02¿ù 04ÀÏ µ¿°ü ´ë°­´ç 10:25~10:40 Myopic disc change vs myopic glaucomatous damage ¹ÚÇý¿µ(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 02¿ù 04ÀÏ µ¿°ü ´ë°­´ç 10:40~10:55 Neuroprotection therapy: where are we? ³ë½Â¼ö(Â÷ÀÇ°úÇдë)

Åä·Ð 02¿ù 04ÀÏ µ¿°ü ´ë°­´ç 10:55~11:05 Discussion ()

±³À°½Ã°£ 02¿ù 04ÀÏ µ¿°ü ´ë°­´ç 11:20~11:40 Challenging conventions in angle closure Benjamin Xu(University of Southern California, USA)

Åä·Ð 02¿ù 04ÀÏ µ¿°ü ´ë°­´ç 11:40~11:50 Discussion ()

±³À°½Ã°£ 02¿ù 04ÀÏ µ¿°ü ´ë°­´ç 11:50~12:10 Why is myopia a confounding factor for glaucoma diagnosis? Hitomi Saito(University of Tokyo, Japan)

Åä·Ð 02¿ù 04ÀÏ µ¿°ü ´ë°­´ç 12:10~12:20 Discussion ()

±³À°½Ã°£ 02¿ù 04ÀÏ µ¿°ü ´ë°­´ç 13:30~13:40 Gonioscopy vs AS-OCT - prefer gonioscopy ±è´ë¿ì(°æºÏÀÇ´ë)

±³À°½Ã°£ 02¿ù 04ÀÏ µ¿°ü ´ë°­´ç 13:40~13:50 Gonioscopy vs AS-OCT - prefer AS-OCT ¹ÚÁöÇý(°í·ÁÀÇ´ë)

±³À°½Ã°£ 02¿ù 04ÀÏ µ¿°ü ´ë°­´ç 13:50~14:00 Early LPI vs cataract extraction - prefer LPI Á¶À±Çý(°Ç±¹ÀÇ´ë)

±³À°½Ã°£ 02¿ù 04ÀÏ µ¿°ü ´ë°­´ç 14:00~14:10 Early LPI vs cataract extraction - prefer cataract extraction Á¤°æÀÎ(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 02¿ù 04ÀÏ µ¿°ü ´ë°­´ç 14:10~14:20 MIGS in angle closure glaucoma - prefer MIGS ÀÌ°æ¹Î(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 02¿ù 04ÀÏ µ¿°ü ´ë°­´ç 14:20~14:30 MIGS in angle closure glaucoma - no MIGS ÀÌÁö¿õ(ºÎ»êÀÇ´ë)

Åä·Ð 02¿ù 04ÀÏ µ¿°ü ´ë°­´ç 14:30~14:45 Discussion ()

±³À°½Ã°£ 02¿ù 04ÀÏ µ¿°ü ´ë°­´ç 15:00~15:15 Intraocular pressure management after PKP Á¤Á¾Áø(°Ç¾çÀÇ´ë)

±³À°½Ã°£ 02¿ù 04ÀÏ µ¿°ü ´ë°­´ç 15:15~15:30 Thyroid-associated ophthalmopathy induced intractable glaucoma ÃÖÁø¾Æ(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 02¿ù 04ÀÏ µ¿°ü ´ë°­´ç 15:30~15:45 Management of recurrent CMV-positive uveitic glaucoma ¼º¹Ì¼±(Àü³²ÀÇ´ë)

±³À°½Ã°£ 02¿ù 04ÀÏ µ¿°ü ´ë°­´ç 15:45~16:00 Complications after Ahmed valve implantation ¼Û¹Î°æ(ÀÎÁ¦ÀÇ´ë)

Åä·Ð 02¿ù 04ÀÏ µ¿°ü ´ë°­´ç 16:00~16:15 Panel discussion ¹Ú»ó¿ì, À¯Á¤±Ç(Àü³²ÀÇ´ë, °í·ÁÀÇ´ë)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2024 Á¦11ȸ ¾Æ»ê¾È°ú ½ÉÆ÷Áö¾ö-³ì³»Àå : 2024-02-04""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇѽºÆ÷Ã÷ÀÇÇÐȸ (¿Â¶óÀÎ)2024³â ÆÀÇÇÁö¼Ç ¿¬¼ö°­Á : 2024-02-04
´ÙÀ½±Û ´ëÇѽɺÎÀüÇÐȸ µðÁöÅÐÇコ ½ÉÆ÷Áö¾ö : 2024-02-03
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20910 ¼­¿ï 2024³â Á¦14ȸ °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»ºÐºñ³»°ú ¿¬¼ö°­Á : 2024-07-07 0 4 2024-05-28
20909 °æ±â ¾ÆÁÖ´ëÇб³º´¿ø Á¤Çü¿Ü°ú 30Áֳ⠱â³ä ½ÉÆ÷Áö¿ò : 2024-07-07 0 8 2024-05-28
20908 ¼­¿ï Á¦19Â÷ ´ëÇѸðÀ¯¼öÀ¯ÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-07-07 0 9 2024-05-28
20907 °æ±â Á¦2Â÷ ´ëÇѽŰæ¹æ»ç¼±¼ö¼úÇÐȸ Á¤±âÇмú´ëȸ : 2024-07-06 0 8 2024-05-28
20906 °æ±â Á¦ 5ȸ ¿À»ê½ÃÀÇ»çȸ Çмú´ëȸ : 2024-07-06 0 5 2024-05-28
20905 ¼­¿ï ¼­¿ï¾Æ»êº´¿ø Á¦3ȸ ¾Æ»êµÎ°æºÎ Æ÷·³ : 2024-07-06 0 8 2024-05-28
20904 ¼­¿ï 2024³â Á¦2ȸ °¡Å縯´ëÇб³ ÀºÆò¼º¸ðº´¿ø ¼øȯ±â³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-07-06 0 9 2024-05-28
20903 ¼­¿ï ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ENDO 2024 (Day3) : 2024-07-06 0 9 2024-05-28
20902 ¼­¿ï ´ëÇѽŰæÁýÁßÄ¡·áÇÐȸ 2024³â ÇÏ°è NeurocrItical Care Essence (NICE) ¾ÆÄ«µ¥¹Ì : 2024-07-06 0 5 2024-05-28
20901 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø Á¦10ȸ ºÎ½Å¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-07-06 0 2 2024-05-28
20900 ¼­¿ï ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ENDO 2024 (Day2) : 2024-07-05 0 4 2024-05-28
20899 ¼­¿ï ÀÓ»ó¼ú±â±³À°¿¬±¸È¸ Á¦16ȸ ÀÓ»ó¼ú±â ¿¬¼ö°­Á : 2024-07-04 0 8 2024-05-28
20898 °æ±â ¿ëÀμ¼ºê¶õ½ºº´¿ø µðÁöÅÐÀÇ·á½ÉÆ÷Áö¾ö -¹Ì·¡ ÀǷḦ À§ÇÑ ±³·ù¿Í Çù·Â : 2024-07-04 0 3 2024-05-28
20897 ¼­¿ï ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ENDO 2024 (Day1) : 2024-07-04 0 4 2024-05-28
20896 ¼­¿ï ´ëÇÑ»êºÎÀΰúÇÐȸ ¼­ºÎÁöȸ Á¤±â Áý´ãȸ(Àڱ󻸷Áõ½ÄÁõ) : 2024-07-02 0 5 2024-05-28
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷